Recombinant mouse perlecan domain I (1 73 residues) was produced in transfected embryonic kidney cells and purified from the culture medium on DEAE-cellulose. It was shown to be modified by glycosaminoglycans and could be partially separated into two protein pools which were either substituted with heparan sulfate (fragment 1A) or, to a smaller extent (20%), with chondroitiddermatan sulfate or a mixture of both glycosaminoglycans (fragment IB). The average molecular mass of the glycosaminoglycans was about 8-10 kDa and, thus, smaller than in tissue-derived perlecans. Sequence and carbohydrate analyses localized the heparan sulfate attachment site to three Ser residues within SGD consensus sequences. Furthermore, the N-terminal part of fragment IA contained six Thr/Ser residues substituted by branched galactosamine-containing oligosaccharides and an N-substituted Asn residue. Fragment I was also shown to contain unique immunological epitopes which are not dependent on glycosaminoglycans and are shared by tissue-derived perlecan. Circular dichroism demonstrated a distinct a helix (20%) and p structure (60%) in fragment TA, consistent with predictions of a novel SEA protein module located in the C-terminal part of domain I.Keywords: basement membrane; protein module ; proteoglycan : recombinant production.Perlecan consists of a 480-kDa protein core substituted by three glycosaminoglycan side chains and is known to be the most abundant basement membrane proteoglycan (Timpl, 1993 ;Iozzo et al., 1994). Electron microscopy demonstrated an elongated core protein of about 80 nm and the asymmetric attachment of the glycosaminoglycans to one end of the core (Paulsson et al., 1987). Sequence analysis of mouse and human perlecan cDNA predicted a complex modular structure for the protein core and the module arrangement was interpreted to indicate the presence of five distinct domains I-V (Noonan et al., 1991 : Kallunki andTryggvason, 1992; Murdoch et al., 1992). These domains form alternating globular and rod-like structures as shown for tissue-derived perlecan and some of its recombinant domains (Paulsson et al., 1987;Schulze et al., 1995; Chakravarti et al., 1995). Several functional properties have been localized to the core protein, including binding to nidogen and fibulin-2 (Battaglia et al., 1992;Sasaki et al., 1995), cell attachment mediated through integrin receptors (Hayashi et al., 1992;Battaglia et al., 1993; Chakravarti et al., 1995) and anti-adhesive effects for bone-marrow-derived cells (Klein et al., 1994). The heparan sulphate chains of perlecan serve different purposes, however, and bind to fibronectin, collagen IV and laminin-1 (Battaglia et al., 1993) and to basic fibroblast growth factor, thereby modulating its storage and receptor binding (Aviezer et al., 1994; Whitelock et al., 1995); they may also be involved in the control of renal filtration and proteolytic degradation (Timpl, 1993 Most perlecan forms isolated from tumor basement membranes (Hassell et al., 1985; Paulsson et al., 1987) or fibrob...